Resolution Therapeutics Announces the Appointment of Lisa Bright as Chair of its Board of Directors
Experienced Non-Executive Director with strategic and operational leadership in global companies
London, 9 November 2022 – Resolution Therapeutics Limited (“Resolution”), a biopharmaceutical company developing macrophage cell therapies to treat advanced liver disease, today announced that Lisa Bright, a Board Director of Resolution since April 2021, has been appointed as Chair of its Board of Directors. Dr Edward Hodgkin has acted as Chair and Chief Executive Officer since the Company’s inception in 2020, and he will remain as Chief Executive Officer of Resolution. Lisa brings skills to the Board in strategic, commercial and operational leadership in global market leading pharmaceutical and emerging biotech companies gained over her 30-year career in the industry.
“I have worked closely with Lisa since she joined Resolution as a Board Director. She is an exceptional leader with a strong track record of successfully guiding organisations from development to commercialisation,” said Edward Hodgkin, Senior Partner of Syncona Investment Management Limited who serves as CEO of Resolution. “I am delighted to welcome her now as Chair of Resolution as we grow into an industry-leading company with a pipeline of macrophage cell therapies designed for patients with advanced liver disease.”
Between 2014 and January 2021, Lisa Bright served on the executive team of Intercept Pharmaceuticals Inc., a global biopharmaceutical company focused on the development and commercialisation of novel therapeutics in liver disease as President International and, prior to that, Chief Commercial and Corporate Affairs Officer. Previously, Lisa held various Vice President positions at Gilead Sciences Inc., including Head of HCV launch planning ex-US, Regional General Manager of Northern Europe and Head of Government Affairs ex-US. Lisa also held VP-level general management and commercial roles at GlaxoSmithKline plc. Lisa is a Non-Executive Director at Ascendis Pharma A/S, Dechra Pharmaceuticals Plc, Immedica Pharma AB and the Centre for Disease Analysis Foundation. She is a strategic advisor to Syncona and DRI Capital.
“I am delighted to serve as Chair of Resolution,” added Lisa Bright. “Despite the amazing scientific progress in liver disease over recent years, there are few treatment options for people who develop liver cirrhosis. I am excited to continue working with Edward, his talented team and the Board at such an important time in the Company’s evolution, as its lead program, an engineered macrophage cell therapy to treat liver cirrhosis, progresses towards the clinic.”
– Ends –
+44 (0)7818 430877
Notes for Editors:
Resolution Therapeutics is a biotechnology company developing macrophage cell therapies to treat advanced liver disease. The Company is built upon more than a decade of work in the Founders’ laboratories characterising the role of macrophages in organ repair, including the liver, both in the pre-clinical and clinical settings. Resolution will discover, develop, and take to market macrophage cell therapies based on its proprietary platform of macrophage biology, cell engineering and manufacturing processes. www.resolution-tx.com